Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. It is characterized by a chronic, progressive, fibrotic interstitial lung disease of unknown cause that occurs primarily in older adults. Its prevalence and incidence have appeared to be increasing over the last decades. Despite its unknown nature, several genetic and environmental factors have been associated with IPF. Moreover, its natural history is variable, but could change depending on the currently suggested phenotypes: rapidly progressive IPF, familial, combined pulmonary fibrosis and emphysema, pulmonary hypertension, and that associated with connective tissue diseases. Early recognition and accurate staging are likely to improve outcomes and induce a prompt initiation of antifibrotics therapy. Treatment is expected to be more effective in the early stages of the disease, while developments in treatment aim to improve the current median survival of 3–4 years after diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 1×
“Nintedanib, a tyrosine kinase inhibitor that targets growth factor pathways, and pirfenidone, a pleiotropic drug with anti-inflammatory and antifibrotic effects, slow the rate of forced vital capacity (FVC) decline by approximately 50% over the course of one year [51,52] and have shown a reduction in mortality [53,54].”
BackgroundA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975 · cited 1×
“Nintedanib, a tyrosine kinase inhibitor that targets growth factor pathways, and pirfenidone, a pleiotropic drug with anti-inflammatory and antifibrotic effects, slow the rate of forced vital capacity (FVC) decline by approximately 50% over the course of one year [51,52] and have shown a reduction in mortality [53,54].”
BackgroundLederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056 · cited 7×
“It is considered a rare disease, but recent prevalence and incidence rates appear to be on the rise, probably due to greater awareness, population ageing, male sex, or other factors (see below) [2].”
BackgroundInfluentialRicheldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020 · cited 1×
“Idiopathic pulmonary fibrosis is a disease of unknown cause, but there is an interaction between genetic and environmental risk factors [17].”
BackgroundRaghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · cited 1×
“The natural history of the disease is variable and difficult to predict [45].”
BackgroundAcute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444 · cited 2×
“Each year, about 10% to 20% of patients with IPF have an acute exacerbation, which is characterized by the worsening of hypoxemic respiratory failure with bilateral ground-glass opacities, consolidation, or both on high-resolution CT imaging that can lead to their death [46].”
BackgroundTelomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 1×
“Mutations in TERT, TERC, PARN, and RTEL1—genes involved in the maintenance of telomere length—are associated with an increased risk of IPF [19].”
BackgroundGenome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.02.001 · Cited by 463
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30326-5 · Cited by 335 · cited 1×
“Nintedanib, a tyrosine kinase inhibitor that targets growth factor pathways, and pirfenidone, a pleiotropic drug with anti-inflammatory and antifibrotic effects, slow the rate of forced vital capacity (FVC) decline by approximately 50% over the course of one year [51,52] and have shown a reduction in mortality [53,54].”
BackgroundAllen, R. J., Porte, J., Braybrooke, R., Flores, C., Fingerlin, T. E., Oldham, J. M., Guillen-Guio, B., Ma, S.-F., Okamoto, T., John, A. E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30387-9 · Cited by 297 · cited 1×
“Variations in genes (DSP, AKAP13, CTNNA, and DPP9) responsible for cell adhesion, integrity, and mechanic transduction (the generation of electrical signals from a mechanical stimulus) also confer a predisposition to IPF [20,21].”
BackgroundMeasuring global health: motivation and evolution of the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32367-x · Cited by 191
Natural history of idiopathic pulmonary fibrosis
Kim, H. J., Perlman, D., & Tomic, R. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.002 · Cited by 191 · cited 2×
“Early referral to ILD specialty centers is important for accurate diagnosis and to start therapies that are effective (antifibrotics), even in the early stages of disease, and may be associated with improved outcomes [44].”
BackgroundLung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
Kistler, K. D., Nalysnyk, L., Rotella, P., & Esser, D. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-139 · Cited by 151 · cited 1×
“Whether bilateral is superior to single-lung transplantation in patients with IPF is still unclear, although observational studies and available databases suggest improved outcomes with bilateral transplantation [60].”
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis
Huang, Y., Ma, S.-F., Espindola, M. S., Vij, R., Oldham, J. M., Huffnagle, G. B., Erb-Downward, J. R., Flaherty, K. R., Moore, B. B., White, E. S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1525oc · Cited by 142 · cited 1×
“There are also some studies that relate IPF risk, microbiome diversity, host defense pathways (MUC5B, ATP11A, TOLLIP), and disease progression [25,26].”
BackgroundGribbin, J., Hubbard, R., & Smith, C. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.001 · Cited by 132
Cited by
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17
Sullivan, D. I., Jiang, M., Hinchie, A. M., Roth, M. G., Bahudhanapati, H., Nouraie, M., Liu, J., McDyer, J. F., Mallampalli, R. K., Zhang, Y., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.600626 · Cited by 16
Caveolin-1 scaffolding domain peptide abrogates autophagy dysregulation in pulmonary fibrosis
Venkatesan, S., Fan, L., Tang, H., Konduru, N. V., & Shetty, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14832-4 · Cited by 11
Metadata
- Authors
- Sauleda, J., Núñez, B., Sala, E., & Soriano, J. B.
- Venue
- Medical Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-29
- Volume
- 6
- Issue
- 4
- Pages
- 110
- ISSN
- 2076-3271 (ISSN-L)
- OpenAlex
- W2902041602
- Cited by
- 137
- References
- 19
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.